<DOC>
	<DOC>NCT00189787</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.</brief_summary>
	<brief_title>Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Diagnosis of asthma Patients treated with inhaled corticosteroid FEV1 (forced expiratory volume in 1 second)&gt;60% to 80% Respiratory infection within 2 weeks Asthma exacerbation within 90 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>Anti-asthmatic drug</keyword>
	<keyword>Administration, inhalation</keyword>
</DOC>